386 related articles for article (PubMed ID: 33713215)
21. Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan.
Ogata M; Kotaka M; Ogata T; Hatachi Y; Yasui H; Kato T; Tsuji A; Satake H
PLoS One; 2020; 15(6):e0234314. PubMed ID: 32530932
[TBL] [Abstract][Full Text] [Related]
22. Impact of KRAS
Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T
ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240
[TBL] [Abstract][Full Text] [Related]
23. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
[TBL] [Abstract][Full Text] [Related]
24. Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada.
Ding PQ; Dolley A; Cheung WY
Curr Oncol; 2022 Dec; 30(1):130-144. PubMed ID: 36661660
[TBL] [Abstract][Full Text] [Related]
25. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey.
Özet A; Dane F; Aykan NF; Yalçın Ş; Evrensel T; Özkan M; Karabulut B; Ormeci MN; Atasev O; Vidot L; Çiçin İ
Future Oncol; 2022 Sep; 18(29):3267-3276. PubMed ID: 36040321
[No Abstract] [Full Text] [Related]
26. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
Saif MW; Becerra CR; Fakih MG; Sun W; Popovic L; Krishnamurthi S; George TJ; Rudek MA; Shepard DR; Skopek J; Sramek V; Zaric B; Yamamiya I; Benhadji KA; Hamada K; He Y; Rosen L
Cancer Chemother Pharmacol; 2021 Sep; 88(3):485-497. PubMed ID: 34097100
[TBL] [Abstract][Full Text] [Related]
27. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
28. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
[TBL] [Abstract][Full Text] [Related]
29. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
[TBL] [Abstract][Full Text] [Related]
30. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J; Ma X; Ooft SN; van der Helm PW; Hoes LR; Mainardi S; Pinato DJ; Sun K; Salvatore L; Tortora G; Zurlo IV; Leo S; Giampieri R; Berardi R; Gelsomino F; Merz V; Mazzuca F; Antonuzzo L; Rosati G; Stavraka C; Ross P; Rodriquenz MG; Pavarana M; Messina C; Iveson T; Zoratto F; Thomas A; Fenocchio E; Ratti M; Depetris I; Cergnul M; Morelli C; Libertini M; Parisi A; De Tursi M; Zanaletti N; Garrone O; Graham J; Longarini R; Gobba SM; Petrillo A; Tamburini E; La Verde N; Petrelli F; Ricci V; Wessels LFA; Ghidini M; Cortellini A; Voest EE; Valeri N
Nat Med; 2023 Mar; 29(3):605-614. PubMed ID: 36864254
[TBL] [Abstract][Full Text] [Related]
31. Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.
Masuishi T; Taniguchi H; Kawakami T; Kawamoto Y; Kadowaki S; Onozawa Y; Muranaka T; Tajika M; Yasui H; Nakatsumi H; Yuki S; Muro K; Omae K; Komatsu Y; Yamazaki K
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32392174
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of trifluridine and tipiracil hydrochloride in the treatment of metastatic colorectal cancer in Greece.
Gourzoulidis G; Maniadakis N; Petrakis D; Souglakos J; Pentheroudakis G; Kourlaba G
J Comp Eff Res; 2019 Feb; 8(3):133-142. PubMed ID: 30547679
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece.
Gourzoulidis G; Koulentaki M; Koumarianou A; Samadas E; Androulakis N; Xynogalos S; Papakotoulas P; Boukovinas I; Karamouzis M; Souglakos J; Chotzagiannoglou V; Beletsi A; Kourlaba G
Expert Rev Pharmacoecon Outcomes Res; 2022 Mar; 22(2):259-269. PubMed ID: 33900864
[TBL] [Abstract][Full Text] [Related]
34. Post-marketing surveillance study of trifluridine/tipiracil in patients with metastatic colorectal cancer.
Yoshino T; Uetake H; Funato Y; Yamaguchi Y; Koyama T; Ozawa D; Tajiri M; Muro K
Jpn J Clin Oncol; 2021 Apr; 51(5):700-706. PubMed ID: 33438718
[TBL] [Abstract][Full Text] [Related]
35. Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
Signorelli C; Gemma D; Grande R; DE Marco S; Saltarelli R; Morandi MG; Spinelli GP; Zoratto F; Sperduti I; Chilelli MG; Ceribelli A; Ruggeri EM
Anticancer Res; 2021 May; 41(5):2553-2561. PubMed ID: 33952483
[TBL] [Abstract][Full Text] [Related]
36. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Tabernero J; Alsina M; Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Ando T; Yalçın Ş; Van Cutsem E; Sabater J; Skanji D; Leger C; Amellal N; Ilson DH
Gastric Cancer; 2020 Jul; 23(4):689-698. PubMed ID: 32128634
[TBL] [Abstract][Full Text] [Related]
37. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
[TBL] [Abstract][Full Text] [Related]
38. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
[TBL] [Abstract][Full Text] [Related]
39. Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil.
Hashimoto I; Kano K; Onuma S; Suematsu H; Nagasawa S; Kanematsu K; Furusawa K; Hamaguchi T; Watanabe M; Hayashi K; Furuta M; Inokuchi Y; Machida N; Aoyama T; Yamada T; Rino Y; Ogata T; Oshima T
J Pers Med; 2023 May; 13(6):. PubMed ID: 37373912
[TBL] [Abstract][Full Text] [Related]
40. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
